Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.

Abstract excerpt

DDR (DNA damage response) defects in cells drive tumor formation by promoting DNA mutations, which also provides cancer-specific vulnerabilities that can be targeted by synthetic lethality-based therapies. Until now, PARP inhibitors like olaparib are the first successful case of utilizing synthetic lethality-based therapy to treat cancers with DNA-repairing deficiency (e.g. BRCA1 or BRCA2 mutation), which has...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to DNA Damage
• Share to DNA Repair
• Share to Mutation